Targeted Therapy for Mesothelioma

Several actors died from mesothelioma due to asbestos exposure, including Steve McQueen (1930-1980), diagnosed with pleural mesothelioma in 1978 after possible exposure from military service and movie sets, dying at age 50. Paul Gleason (1939-2006), known for *The Breakfast Club*, developed pleural mesothelioma from teenage construction work and died three weeks after diagnosis at age 67. Ed Lauter (1938-2013), a character actor in over 200 films, was diagnosed in 2013, possibly from home renovations, and died months later at age 74.

Evidence from multiple cancer types indicates that targeted therapies often improve life expectancy, particularly when tumors carry specific actionable mutations. In advanced non-small cell lung cancer with targetable drivers, median overall survival has increased from about 17 months with chemotherapy alone to roughly 45 months with targeted drugs, and some ALK‑positive lung cancers remain controlled for 5 years or longer. In gastrointestinal stromal tumors treated with imatinib, about 20% of people with advanced disease have survived 10 years, with around 10% progression free at that time. Chronic lymphocytic leukemia outcomes have also improved, with drugs like ibrutinib associated with survival approaching that of the general population. These gains are not universal, and benefit varies by cancer type, mutation, and response to treatment, so targeted therapy has not eliminated the life expectancy gap for many people with mesothelioma or other aggressive cancers.

Targeted therapy can be more effective than chemotherapy for cancers driven by a specific molecular alteration, such as EGFR-mutated non small cell lung cancer, HER2-positive breast cancer, or BRAF-mutated melanoma, where studies report higher response rates and longer progression-free survival compared with standard chemo. In renal cell carcinoma, an analysis found people treated with targeted therapy had a 1-year survival of 55% vs 49% with non targeted treatment and a median survival that was 3.0 months longer. For many cancers without a clear target, chemotherapy still achieves better or more reliable control, which is why it remains a cornerstone of treatment. In practice, evidence shows that some people benefit most from targeted drugs alone, others from chemotherapy, and many from combinations or sequences of both over the course of their care.

No single treatment is clearly “most effective” for all people with mesothelioma, because outcomes depend heavily on cancer stage, cell type, overall health, and whether the disease is resectable. For eligible people, surgery combined with chemotherapy and sometimes radiation or immunotherapy (multimodal therapy) is linked to the longest survival, including 5‑year survival rates of about 50% to 69% for some people with peritoneal mesothelioma who receive cytoreductive surgery plus HIPEC. For unresectable pleural mesothelioma, first‑line immunotherapy with nivolumab plus ipilimumab is now FDA‑approved and has improved overall survival compared with chemotherapy alone, with higher 2‑ and 3‑year survival rates. Standard chemotherapy, typically pemetrexed with cisplatin or carboplatin, remains the most commonly used systemic treatment and can shrink tumors, slow progression, and relieve symptoms. Targeted drugs such as bevacizumab and newer immunotherapy combinations are being actively studied in clinical trials, which report additional survival gains for some people.